Abstract
188P - The impact of Oncotype DX breast cancer assay results on clinical practice: A UK experience
Highlights
Breast cancer is one of the most commonly diagnosed cancers in women worldwide, with over 250,000 new cases diagnosed in the US in 2017 (30% of the total new cancer diagnoses in women that year) [1]
Concordance between high-risk Recurrence Scores (RS) and RSPC decreased to 69.1%, with a higher proportion of patients being reclassified as intermediate risk according to RSPC. These results from a real-world series of over 700 UK patients show that 73.3% of those who underwent the Oncotype DX assay did not receive adjuvant chemotherapy. 49.8% of patients had a low-risk RS (< 18), which is in keeping with other UK results [23], and is similar to the results found in a meta-analysis of international studies [24]
Interpretation of RS scores may vary between clinicians or institutions, which may in part reflect varying levels of familiarity with the test; in our data the range of the number of tests performed per institution ranged from 5 to 136
Summary
Breast cancer is one of the most commonly diagnosed cancers in women worldwide, with over 250,000 new cases diagnosed in the US in 2017 (30% of the total new cancer diagnoses in women that year) [1]. The current UK standard of care in early-stage (nodenegative) oestrogen receptor-positive (ER+), human epidermal growth factor 2-negative (HER2−) breast cancer is surgery followed by adjuvant endocrine therapy, with or without the addition of systemic chemotherapy [4, 5]. Not all patients require adjuvant chemotherapy and endocrine therapy after surgery. Genomic tests are increasingly being used by clinicians when considering adjuvant chemotherapy for patients with oestrogen receptor-positive (ER+), human epidermal growth factor 2-negative (HER2−) breast cancer. Risk by RS-pathology-clinical (RSPC) was calculated and compared to the low/intermediate/ risk categories, both as originally defined (RS < 18, 18–30 and > 30) and using redefined boundaries (RS < 11, 11–25 and > 25). Conclusions This real-world data demonstrate the value of genomic tests in reducing the use of adjuvant chemotherapy in breast cancer. Incorporating clinical characteristics or RSPC scores gives additional prognostic information which may aid clinicians’ decision making
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
